Adenosine triphosphate. Established and potential clinical applications

Drugs

Volumn 58, Issue 2, 1999, Pages 211-232

  Agteresch, Hendrik J ^a   Dagnelie, Pieter C ^a,b   Van Den Berg, J Willem O ^a   Wilson, J H Paul ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; AMILORIDE; CYTOSTATIC AGENT; GAMMA INTERFERON; GLYCOGEN; KETAMINE; MORPHINE; OPIATE; PURINE P2 RECEPTOR; SODIUM CHANNEL BLOCKING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANESTHESIA; BREATHING DISORDER; CACHEXIA; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DRUG POTENTIATION; GLYCOGEN METABOLISM; HEADACHE; HEART FUNCTION; HEMORRHAGIC SHOCK; HOT FLUSH; HUMAN; HYPERALGESIA; HYPOTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MUCOCILIARY CLEARANCE; MUSCLE CONTRACTION; NAUSEA; NEUROPATHY; NEUROTRANSMISSION; NONHUMAN; PAIN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PULMONARY HYPERTENSION; RADIATION INJURY; REVIEW; THROMBOCYTE FUNCTION; VASODILATATION; WEIGHT REDUCTION;

ADENOSINE DIPHOSPHATE; ANESTHESIA; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; LUNG DISEASES; NEOPLASMS;

EID: 0032814775     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958020-00002     Document Type: Review

References (311)

1. 1. Forrester T, Lind AR. Identification of adenosine triphosphate in human plasma and the concentration in the venous effluent of forearm muscles before, during and after sustained contractions. J Physiol (Lond) 1969; 204 (2): 347-64
2. 2. Fredholm BB, Abbracchio MP, Burnstock G, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 1997; 18 (3): 79-82
3. 2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19: 148-53
4. 4. Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 1994; 64 (3): 445-75
5. 5. Dubyak GR, el-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993; 265 (3): C577-606
6. 2+ mobilizing receptors for ATP and UTP. Cell Calcium 1995; 17 (2): 111-9
7. 7. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140 (1): 1-22
8. 8. Torrance JD, Whittaker D. Distribution of erythrocyte nucleotides in pyrimidine 5′-nucleotidase deficiency. Br J Haematol 1979; 43 (3): 423-34
9. 9. de Korte D, Haverkort WA, van Gennip AH, et al. Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Anal Biochem 1985; 147 (1): 197-209
10. 10. Werner A, Siems W, Schmidt H, et al. Determination of nucleotides, nucleosides and nucleobases in cells of different complexity by reversed-phase and ion pair high-performance liquid chromatography. J Chromatogr 1987; 421 (2): 257-65
11. 11. Harkness RA, Simmonds RJ, Coade SB. Purine transport and metabolism in man: the effect of exercise on concentrations of purine bases, nucleosides and nucleotides in plasma, urine, leucocytes and erythrocytes. Clin Sci 1983; 64 (3): 333-40
12. 12. Ryan LM, Rachow JW, McCarty BA, et al. Adenosine triphosphate levels in human plasma. J Rheumatol 1996; 23 (2): 214-9
13. 13. Ontyd J, Schrader J. Measurement of adenosine, inosine, and hypoxanthine in human plasma. J Chromatogr 1984; 307 (2): 404-9
14. 14. Parker JC. Metabolism of external adenine nucleotides by human red blood cells. Am J Physiol 1970; 218 (6): 1568-74
15. 15. Schrader J, Berne RM, Rubio R. Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 1972; 223 (1): 159-66
16. 16. Trams EG. A proposal for the role of ecto-enzymes and adenylates in traumatic shock. J Theor Biol 1980; 87 (3): 609-21
17. 17. Haskell CM, Wong M, Williams A, et al. Phase I trial of extracellular adenosine 5′-triphosphate in patients with advanced cancer. Med Pediatr Oncol 1996; 27 (3): 165-73
18. 18. Rapaport E, Fontaine J. Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice. Biochem Pharmacol 1989; 38 (23): 4261-6
19. 19. Lerner MH, Lowy BA. The formation of adenosine in rabbit liver and its possible role as a direct precursor of erythrocyte adenine nucleotides. J Biol Chem 1974; 249 (3): 959-66
20. 20. Rapaport E, Fontaine J. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc Natl Acad Sci U S A 1989; 86 (5): 1662-6
21. 21. Rapaport E. Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol 1988; 24 (9): 1491-7
22. 22. Rapaport E. Mechanisms of anticancer activities of adenine nucleotides in tumor-bearing hosts. Ann N Y Acad Sci 1990; 603: 142-9
23. 23. Shapiro MJ, Jellinek M, Pyrros D, et al. Clearance and maintenance of blood nucleotide levels with adenosine triphosphate-magnesium chloride injection. Circ Shock 1992; 36 (1): 62-7
24. 24. Binet L, Burstein M. Poumon et action vasculaire de l'adenosine-triphosphate (ATP). Presse Med 1950; 58 (68): 1201-3
25. 25. Paddle BM, Burnstock G. Release of ATP from perfused heart during coronary vasodilatation. Blood Vessels 1974; 11 (3): 110-9
26. 26. Ryan JW, Smith U. Metabolism of adenosine 5′-monophosphate during circulation through the lungs. Trans Assoc Am Physicians 1971; 134: 297-306
27. 27. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989; 256 (4): C799-806
28. 28. Ryun US, Ryan JW, Crutchley DJ. The pulmonary endothelial surface. Fed Proc 1985; 44 (10): 2603-9
29. 29. Pearson JD, Carleton JS, Gordon JL. Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture. Biochem J 1980; 190 (2): 421-9
30. 30. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J 1986; 233 (2): 309-19
31. 31. Coade SB, Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res 1989; 65 (3): 531-7
32. 32. Barankiewicz J, Dosch HM, Cohen A. Extracellular nucleotide catabolism in human B and T lymphocytes.: the source of adenosine production. J Biol Chem 1988; 263 (15): 7094-8
33. 33. Filippini A, Taffs RE, Agui T, et al. Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem 1990; 265 (1): 334-40
34. 34. Schwarzbaum PJ, Frischmann ME, Krumschnabel G, et al. Functional role of ecto ATPase activity in goldfish hepatocytes. Am J Physiol 1998; 274 (4): R1031-8
35. 35. Gordon EL, Pearson JD, Slakey LL. The hydrolysis of extracellular adenine nucleotides by cultured endothelial cells from pig aorta: feed-forward inhibition of adenosine production at the cell surface. J Biol Chem 1986; 261 (33): 15496-507
36. 36. Sawynok J, Sweeney MI. The role of purines in nociception. Neuroscience 1989; 32 (3): 557-69
37. 37. Sawynok J, Sweeney MI, White TD. Adenosine release may mediate spinal analgesia by morphine. Trends Pharmacol Sci 1989; 10 (5): 186-9
38. 38. Salter MW, Henry JL. Effects of adenosine 5′-monophosphate and adenosine 5′-triphosphate on functionally identified units in the eat spinal dorsal born. Evidence for a differential effect of adenosine 5′-triphosphate on nociceptive vs non-nociceptive units. Neuroscience 1985; 15 (3): 815-25
39. 39. Geiger JD, LaBella FS, Nagy JI. Characterization and localization of adenosine receptors in rat spinal cord. J Neurosci 1984; 4 (9): 2303-10
40. 2 adenosine receptors in the rat spinal cord. J Pharmacol Exp Ther 1987; 242 (3): 905-10
41. 2 receptors of the substantia gelatinosa are located predominantly on intrinsic neurons: an autoradiography study. J Pharmacol Exp Ther 1988; 247 (2): 757-64
42. 42. Rice WR, Burton FM, Fiedeldey DT. Cloning and expression of the alveolar type II cell P2u-purinergic receptor. Am J Respir Cell Mol Biol 1995; 12 (1): 27-32
43. 43. Gobran LI, Rooney SA. Adenylate cyclase-coupled ATP receptor and surfactant secretion in type II pneumocytes from newborn rats. Am J Physiol 1997; 272 (2): L187-96
44. 44. Clarke LL, Boucher RC. Chloride secretory response to extracellular ATP in human normal and cystic fibrosis nasal epithelia. Am J Physiol 1992; 263 (2): C348-56
45. 45. Clarke LL, Grubb BR, Yankaskas JR, et al. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr (-/-) mice. Proc Natl Acad Sci U S A 1994; 91 (2): 479-83
46. 46. Stutts MJ, Fitz JG, Paradiso AM, et al. Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP. Am J Physiol 1994; 267 (5): C1442-51
47. 47. Cantiello HF, Prat AG, Reisin IL, et al. External ATP and its analogs activate the cystic fibrosis transmembrane conductance regulator by a cyclic AMP-independent mechanism. J Biol Chem 1994; 269 (15): 11224-32
48. 48. Reisin IL, Prat AG, Abraham EH, et al. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J Biol Chem 1994; 269 (32): 20584-91
49. 49. Reddy MM, Quinton PM. Hydrolytic and nonhydrolytic interactions in the ATP regulation of CFTR Cl-conductance. Am J Physiol 1996; 271 (1): C35-42
50. 50. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325 (8): 533-8
51. 51. Mason SJ, Paradiso AM, Boucher RC. Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br J Pharmacol 1991; 103 (3): 1649-56
52. 52. Lustig KD, Shiau AK, Brake AJ, et al. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc Natl Acad Sci U S A 1993; 90 (11): 5113-7
53. 53. Parr CE, Sullivan DM, Paradiso AM, et al. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci U S A 1994; 91 (8): 3275-9
54. 54. Communi D, Boeynaems JM. Receptors responsive to extracellular pyrimidine nucleotides. Trends Pharmacol Sci 1997; 18 (3): 83-6
55. 55. Abraham EH, Vos P, Kahn J, et al. Cystic fibrosis hetero-and homozygosity is associated with inhibition of breast cancer growth. Nat Med 1996; 2 (5): 593-6
56. 56. Abraham EH, Okunieff P, Scala S, et al. Cystic fibrosis transmembrane conductance regulator and adenosine triphosphate. Science 1997; 275 (5304): 1324-6
57. 57. Reddy MM, Quinton PM, Haws C, et al. Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP. Science 1996; 271 (5257): 1876-9
58. 58. Di Virgilio F, Pizzo P, Zanovello P, et al. Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immunol Today 1990; 11 (8): 274-7
59. 59. Zanovello P, Bronte V, Rosato A, et al. Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol 1990; 145 (5): 1545-50
60. 60. Avery RK, Bleier KJ, Pasternack MS. Differences between ATP-mediated cytotoxicity and cell-mediated cytotoxicity. J Immunol 1992; 149 (4): 1265-70
61. 61. Correale P, Giuliano M, Tagliaferri P, et al. Role of adenosine 5′ triphosphate in lymphokine activated (LAK) killing of human tumor cells. Res Commun Mol Pathol Pharmacol 1995; 87 (1): 67-9
62. 62. Correale P, Tagliaferri P, Guarrasi R, et al. Extracellular adenosine 5′ triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. Immunol Lett 1997; 55 (2): 69-78
63. 63. Filippini A, Taffs RE, Sitkovsky MV. Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc Natl Acad Sci U S A 1990; 87 (21): 8267-71
64. 64. Di Virgilio F, Bronte V, Collavo D, et al. Responses of mouse lymphocytes to extracellular adenosine 5′-triphosphate (ATP): lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol 1989; 143 (6): 1955-60
65. 65. Filippini A, Sitkovsky MV. 'Extracellular ATP' hypothesis of cell-cell interactions in the effector phase of the immune response. FASEB J 1990; 4: A1870
66. 66. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 1985; 16 (5): 433-40
67. 67. Houston DA, Burnstock G, Vanhoutte PM. Different P2-purinergic receptor subtypes of endothelium and smooth muscle in canine blood vessels. J Pharmacol Exp Ther 1987; 241 (2): 501-6
68. 68. Kennedy C, Burnstock G. ATP produces vasodilation via P1 purinoceptors and vasoconstriction via P2 purinoceptors in the isolated rabbit central ear artery. Blood Vessels 1985; 22 (3): 145-55
69. 69. Boeynaems JM, Pearson JD. P2 purinoceptors on vascular endothelial cells: physiological significance and transduction mechanisms. Trends Pharmacol Sci 1990; 11 (1): 34-7
70. 70. Utterback DB, Staples ED, White SE, et al. Basis for the selective reduction of pulmonary vascular resistance in humans during infusion of adenosine. J Appl Physiol 1994; 76 (2): 724-30
71. 71. Boeynaems JM, Pirotton S, Van Cocvorden A, et al. P2-purinergic receptors in vascular endothelial cells: from concept to reality. J Recept Res 1988; 8 (1-4): 121-32
72. 72. Liu SF, McCormack DG, Evans TW, et al. Evidence for two P2-purinoceptor subtypes in human small pulmonary arteries. Br J Pharmacol 1989; 98 (3): 1014-20
73. 73. Fiscus RR. Molecular mechanisms of endothelium-mediated vasodilation. Semin Thromb Hemost 1988; 14 Suppl.: 12-22
74. 74. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65 (1): 1-21
75. 75. Belardinelli L, Isenberg G. Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance. Am J Physiol 1983; 244 (5): H734-7
76. 76. Belardinelli L, Giles WR, West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J Physiol (Lond) 1988; 405: 615-33
77. 77. de Jong JW, van der Meer P, van Loon H, et al. Adenosine as adjunct to potassium cardioplegia: effect on function, energy metabolism, and electrophysiology. J Thorac Cardiovasc Surg 1990; 100 (3): 445-54
78. 78. Freilich A, Tepper D. Adenosine and its cardiovascular effects. Am Heart J 1992; 123 (5): 1324-8
79. 79. Zhang C. Electrophysiological effects of different dosage of adenosine triphosphate on normal sinoatrial and atrioventricular node. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih 1992; 20 (2): 98-100, 134
80. 80. Kurachi Y, Nakajima T, Sugimoto T. On the mechanism of activation of muscarinic K+ channels by adenosine in isolated atrial cells: involvement of GTP-binding proteins. Pflugers Arch 1986; 407 (3): 264-74
81. 81. Wayne EJ, Goodwin JF, Stoner HB. The effect of adenosine triphosphate on the electrocardiogram of man and animals. Br Heart J 1949; 11: 55-67
82. 82. Munoz A, Leenhardt A, Sassine A, et al. Atropine antagonizes the effect of adenosine on atrioventricular conduction in closed chest dogs. Circulation 1985; 72 (III): 241
83. 83. Tai CT, Chen SA, Chiang CE, et al. Influence of beta-adrenergic and vagal activity on the effect of exogenous adenosine on supraventricular tachycardia termination. Am J Cardiol 1997; 79 (12): 1628-31
84. 84. DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68 (6): 1254-63
85. 85. Faulds D, Chrisp P, Buckley MM. Adenosine: an evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia. Drugs 1991; 41 (4): 596-624
86. 86. Charest R, Blackmore PF, Exton JH. Characterization of responses of isolated rat hepatocyets to ATP and ADP. J Biol Chem 1985; 260 (29): 15789-94
87. 87. Okajima F, Tokumitsu Y, Kondo Y, et al. P2-purinergic receptors are coupled to two signal transduction systems leading to inhibition of cAMP generation and to production of inositol trisphosphate in rat hepatocytes. J Biol Chem 1987; 262 (28): 13483-90
88. 2+ in T51B rat liver epithelial cells: a study involving single cell measurements. Exp Cell Res 1989; 181 (1): 245-55
89. 2+-mobilizing purinoceptors on rat hepatocytes. Biochem J 1990; 269 (2): 499-502
90. 90. Cha SH, Jung KY, Endou H. Effect of P2Y-purinoceptor stimulation on renal gluconeogenesis in rats. Biochem Biophys Res Commun 1995; 211 (2): 454-61
91. 91. Koike M, Kashiwagura T, Takeguchi N. Gluconeogenesis stimulated by extracellular ATP is triggered by the initial increase in the intracellular Ca2+ concentration of the periphery of hepatocytes. Biochem J 1992; 283 (1): 265-72
92. 92. Saggerson ED, Carpenter CA, Veiga JA. Stimulation of renal gluconeogenesis by exogenous adenine nucleotides. Biochim Biophys Acta 1983; 755 (1): 119-26
93. 93. Edgecombe M, Craddock HS, Smith DC, et al. Diadenosine polyphosphate-stimulated gluconeogenesis in isolated rat proximal tubules. Biochem J 1997; 323 (Pt 2): 451-6
94. 94. Asensi M, Lopez-Rodas A, Sastre J, et al. Inhibition of gluconeogenesis by extracellular ATP in isolated rat hepatocytes. Am J Physiol 1991; 261 (6): R1522-6
95. 95. Lund P, Cornell NW, Krebs HA. Effect of adenosine on the adenine nucleotide content and metabolism of hepatocytes. Biochem J 1975; 152 (3): 593-9
96. 2+-mobilizing hormones. Biochem J 1983; 212 (3): 733-47
97. 97. Keppens S, De Wulf H. Characterization of the liver P2-purinoceptor involved in the activation of glycogen phosphorylase. Biochem J 1986; 240 (2): 367-71
98. 98. Keppens S, Vandekerekhove A, De Wull H. Extracellular ATP and UTP exert similar effects on rat isolated hepatocytes. Br J Pharmacol 1992; 105 (2): 475-9
99. 99. Buxton DB, Robertson SM, Olson MS. Stimulation of glycogenolysis by adenine nucleotides in the perfused rat liver. Biochem J 1986; 237 (3): 773-80
100. 100. Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol 1983; 114 (3): 279-83
101. 101. Roding TJ. De invloed van ATP op in-vitro gekweekte RUC (1) tumorcellen [thesis]. Amsterdam Free University 1977; (Ch. 3): 35-54
102. 102. Spungin B, Friedberg I. Growth inhibition of breast cancer cells induced by exogenous ATP. J Cell Physiol 1993; 157 (3): 502-8
103. 103. Weisman GA, Lustig KD, Lane E, et al. Growth inhibition of transformed mouse fibroblasts by adenine nucleotides occurs via generation of extracellular adenosine. J Biol Chem 1988; 263 (25): 12367-72
104. 104. Lasso de la Vega MC, Terradez P, Obrador E, et al. Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. Biochem J 1994; 298 (1): 99-105
105. 105. Estrela JM, Obrador E, Navarro J, et al. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat Med 1995; 1 (1): 84-8
106. 106. Obrador E, Navarro J, Mompo J, et al. Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo. Biochem J 1997; 325 (1): 183-9
107. 107. Friedberg I, Kucbler D. The role of surface protein kinase in the ATP-induced growth inhibition in transformed mouse fibroblasts. Ann N Y Acad Sci 1990; 603: 513-5
108. 108. Friedberg I, Belzer I, Oged-Plesz O, et al. Activation of cell growth inhibitor by ectoprotein kinase-mediated phosphorylation in transformed mouse fibroblasts. J Biol Chem 1995; 270 (35): 20560-7
109. 109. Rozengurt E, Heppel LA, Friedberg I. Effect of exogenous ATP on the permeability properties of transformed cultures of mouse cell lines. J Biol Chem 1977; 252 (13): 4584-90
110. 110. Dicker P, Heppel LA, Rozengurt E. Control of membrane permeability by external and internal ATP in 3T6 cells grown in serum-free medium. Proc Natl Acad Sci U S A 1980; 77 (4): 2103-7
111. 111. Heppel LA, Weisman GA, Friedberg I. Permeabilization of transformed cells in culture by external ATP. J Membr Biol 1985; 86 (3): 189-96
112. 112. Kitagawa T, Amano F, Akamatsu Y. External ATP-induced passive permeability change and cell lysis of cultured transformed cells: action in serum-containing growth media. Biochim Biophys Acta 1988; 941 (2): 257-63
113. 113. Kitagawa T, Akamatsu Y. Control of membrane permeability by external ATP in mammalian cells: isolation of an ATP-resistant variant from Chinese hamster ovary cells. Biochim Biophys Acta 1986; 860 (2): 185-93
114. 114. Mure T, Sano K, Kitagawa T. Modulation of membrane permeability, cell proliferation and cytotoxicity of antitumor agents by external ATP in mouse tumor cells. Jpn J Cancer Res 1992; 83 (1): 121-6
115. 115. Di Virgilio F, Fasolato C, Steinberg TH. Inhibitors of membrane transport system for organic anions block fura-2 excretion from PC12 and N2A cells. Biochem J 1988; 256 (3): 959-63
116. 116. Bear CE, Li CH. Calcium-permeable channels in rat hepatoma cells are activated by extracellular nucleotides. Am J Physiol 1991; 261 (6): C1018-24
117. 117. Nagelkerke JF, Dogterom P, De Bont HJ, et al. Prolonged high intracellular free calcium concentrations induced by ATP are not immediately cytotoxic in isolated rat hepatocytes: changes in biochemical parameters implicated in cell toxicity. Biochem J 1989; 263 (2): 347-53
118. 118. Zoeteweij JP, van de Water B, de Bont HJ, et al. Calcium-induced cytotoxicity in hepatocytes after exposure to extracellular ATP is dependent on inorganic phosphate: effects on mitochondrial calcium. J Biol Chem 1993; 268 (5): 3384-8
119. 119. Chahwata SB, Cantley LC. Extracellular ATP induces ion fluxes and inhibits growth of Friend erythroleukemia cells. J Biol Chem 1984; 259 (22): 13717-22
120. 120. Zheng LM, Zychlinsky A, Liu CC, et al. Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol 1991; 112 (2): 279-88
121. 121. Wiley JS, Dubyak GR. Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood 1989; 73 (5): 1316-23
122. 122. Wiley JS, Jamieson GP, Mayger W, et al. Extracellular ATP stimulates an amiloride-sensitive sodium influx in human lymphocytes. Arch Biochem Biophys 1990; 280 (2): 263-8
123. 4 receptor-operated ion channel of human lymphocytes: inhibition of ion fluxes by amiloride analogs and by extracellular sodium ions. Arch Biochem Biophys 1992; 292 (2): 411-8
124. 124. Kitagawa T, Akamatsu Y. Modulation of passive permeability by external ATP and cytoskeleton-attacking agents in cultured mammalian cells. Biochim Biophys Acta 1983; 734 (1): 25-32
125. 125. Franseschi C, Abbracchio MP, Barbieri D, et al. Purines and cell death. Drug Dev Res 1996; 39: 442-9
126. 7). Science 1996; 272 (5262): 735-8
127. 127. Spranzi E, Djeu JY, Hoffman SL, et al. Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. Blood 1993; 82 (5): 1578-85
128. 128. Blanchard DK, Hoffman SL, Spranzi E, et al. Killing of human acute myeloid leukemia cells by extracellular ATP: partial characterization of the ATP receptor. Proc Am Assoc Cancer Res 1994; 35 (2273): 381
129. 129. Bretschneider F, Klapperstuck M, Lohn M, ets al. Nonselective cationic currents elicited by extracellular ATP in human B-lymphocytes. Pflugers Arch 1995; 429 (5): 691-8
130. 130. Seetulsingh-Goorah SP, Stewart BW. Extracellular ATP exerts antileukemic effects via a novel P2X receptor. Proc Am Assoc Cancer Res 1998; 39 (449): 66
131. 7 (P2Z) receptor in N18TG-2 cells and NG108 15 cells. J Neurochem 1998; 70 (3): 951-7
132. 132. Chiozzi P, Murgia M, Falzoni S, et al. Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. Biochem Biophys Res Commun 1996; 218 (1): 176-81
133. 133. Saribas AS, Lustig KD, Zhang X, et al. Extracellular ATP reversibly increases the plasma membrane permeability of transformed mouse fibroblasts to large macromolecules. Anal Biochem 1993; 209 (1): 45-52
134. 134. Beyer EC, Steinberg TH. Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages. J Biol Chem 1991; 266 (13): 7971-4
135. 135. Loewenstein WR. The cell-to-cell channel of gap junctions. Cell 1987; 48 (5): 725-6
136. 136. Alves LA, Coutinho-Silva R, Persechini PM, et al. Are there functional gap junctions or junctional hemichannels in macrophages? Blood 1996; 88 (1): 328-34
137. 137. Nees S, Gerbes AL, Willershausen-Zonnchen B, et al. Purine metabolism in cultured coronary endothelial cells. Adv Exp Med Biol 1979; 122B: 25-30
138. 2 receptor through a protein kinase C signaling pathway. Circ Res 1996; 78 (1): 73-81
139. 3 receptors. J Immunol 1997; 158 (11): 5400-8
140. 140. Newby AC. Adenosine and the concept of retaliatory metabolites. Trends Biochem Sci 1984; 9: 42-4
141. 141. Bouma MG, van den Wildenberg FA, Buurman WA. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: established and putative beneficial actions of a retaliatory metabolite. Shock 1997; 8 (5): 313-20
142. 2 restores renal microcirculation following trauma and severe hemorrhage. Can J Physiol Pharmacol 1992; 70 (3): 349-57
143. 143. Chaudry IH, Stephan RN, Dean RE, et al. Use of magnesium-ATP following liver ischemia. Magnesium 1988; 7: 68-77
144. 144. Hirasawa H, Chaundry IH, Baue AE. Improved hepatic function and survival with adenosine triphosphate-magnesium chloride after hepatic ischemia. Surgery 1978; 83 (6): 655-62
145. 2 following hepatic ischemia. Surg Forum 1979; 30: 158-60
146. 2 on portal and hepatic arterial blood flow after hemorrhage and resuscitation. Am J Physiol 1992; 263 (6): G895-900
147. 2 restores the depressed cardiac output following trauma and severe hemorrhage even in the absence of blood resuscitation. Circ Shock 1992; 36 (4): 277-83
148. 148. Chaudry IH, Sayeed MM, Baue AE. Depletion and restoration of tissue ATP in hemorrhagic shock. Arch Surg 1974; 108 (2): 208-11
149. 149. Ohkawa M, Clemens MG, Chaudry IH. Studies on the mechanism of beneficial effects of ATP MgCl2 following hepatic ischemia. Am J Physiol 1983; 244 (5): R695-702
150. 2. Am J Physiol 1984; 246 (5): R799-804
151. 2 on coronary blood flow and myocardial oxygen consumption. Circulation 1985; 72: 311-5
152. 2 treatment after trauma-hemorrhage/resuscitation increases hepatocyte P2-purinoceptor binding capacity. Am J Physiol 1994; 266 (6): R1810-5
153. 2 on altered hepatocyte signal transduction after hemorrhagic shock. Am J Physiol 1997; 272 (6): G1347-54
154. 154. Maggirwar SB, Dhanraj DN, Somani SM, et al. Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun 1994; 201 (2): 508-15
155. 155. Ramkumar V, Nie Z, Rybak LP, et al. Adenosine, antioxidant enzymes and cytoprotection. Trends Pharmacol Sci 1995; 16 (9): 283-5
156. 2 following trauma-hemorrhage and resuscitation: downregulation of inflammatory cytokine (TNF, IL-6) release. J Surg Res 1992; 52 (4): 364-71
157. 157. Bouma MG, Stad RK, van den Wildenberg FA, et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153 (9): 4159-68
158. 158. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996; 270 (2): C522-9
159. 2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol 1996; 117 (8): 1639-44
160. 2 receptors on human monocytes modulate C2 production. Clin Exp Immunol 1984; 57 (2): 454-60
161. 161. Cronstem BN, Levin RI, Belanoff J, et al. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78 (3): 760-70
162. 162. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92 (6): 2675-82
163. 163. Gomaa AA. Characteristics of analgesia induced by adenosine triphosphate. Pharmacol Toxicol 1987; 61 (3): 199-202
164. 164. Seitz PA, ter Riet M, Rush W, et al. Adenosine decreases the minimum alveolar concentration of halothane in dogs. Anesthesiology 1990; 73 (5): 990-4
165. 165. Segerdahl M, Ekblom A, Sjolund KF, et al. Systemic adenosine attenuates touch evoked allodynia induced by mustard oil in humans. Neuroreport 1995; 6 (5): 753-6
166. 166. Segerdahl M, Ekblom A, Sollevi A. The influence of adenosine, ketamine, and morphine on experimentally induced ischemic pain in healthy volunteers. Anesth Analg 1994; 79 (4): 787-91
167. 167. Segerdahl M, Ekblom A, Sandelin K, et al. Peroperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics. Anesth Analg 1995; 80 (6): 1145-9
168. 168. Segerdahl M, Irestedt L, Sollevi A. Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Acta Anaesthesiol Scand 1997; 41 (4): 473-9
169. 169. Belfrage M, Sollevi A, Segerdahl M, et al. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth Analg 1995; 81 (4): 713-7
170. 170. Sollevi A, Belfrage M, Lundeberg T, et al. Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain 1995; 61 (1): 155-8
171. 171. Filkins JP, Buchanan BJ. Protection against endotoxin shock and impaired glucose homeostasis with ATP. Circ Shock 1977; 4 (3): 253-8
172. 172. Zaki MS, Burke JF, Trelstad RL. Protective effects of adenosine triphosphate administration in burns. Arch Surg 1978; 113 (5): 605-10
173. 173. Cikrit D, Gross K, Katz S. Comparative effects of cytoprotective agents in bowel ischemia. Surg Forum 1983; 34: 208-10
174. 174. Chaudry IH. Cellular mechanisms in shock and ischemia and their correction. Am J Physiol 1983; 245 (2): R117-34
175. 175. Chaudry IH. Use of ATP following shock and ischemia [discussion 140-1]. Ann NY Acad Sci 1990; 603: 130-40
176. 176. Chaudry IH, Sayeed MM, Baue AE. Evidence for enhanced uptake of ATP by liver and kidney in hemorrhagic shock. Am J Physiol 1977; 233 (3): R83-8
177. 177. Osias MD, Siegel NJ, Chaudry IH, et al. Postischemic renal failure: accelerated recovery with adenosine triphosphate-magnesium chloride infusion. Arch Surg 1977; 112: 729-31
178. 2. Adv Shock Res 1982; 8: 177-86
179. 2 following shock. Curr Surg 1982; 39 (2): 82-4
180. 2 following prolonged ischemia improves myocardial performance. J Surg Res 1987; 43 (2): 114-7
181. 2 and/or mositol in rabbit lung. Circ Shock 1988; 24: 274
182. 2 restores gut absorptive capacity early after trauma-hemorrhagic shock. Am J Physiol 1993; 264 (5): R977-83
183. 2 for post-ischemic acute renal failure. Circ Shock 1985; 13: 66
184. 184. Davies DF, Gropper AL, Schroeder HA. Circulatory and respiratory effects of adenosine triphosphate in man. Circulation 1951; III: 543-50
185. 185. Fukunaga AF, Kaneko Y, Ichinohe T, et al. Intravenous ATP attenuates surgical stress responses and reduces inhalation anesthetic requirements in humans. Anesthesiology 1990; 73 (3A): A400
186. 186. Coli A, Fabbri G, Lari S, et al. Hypotension controlled with ATP in orthopaedic surgery: incidence of atrio-ventricular conduction disorders. Minerva Anestesiol 1994; 60 (1-2): 21-7
187. 187. Owall A, Jarnberg PO, Brodin LA, et al. Effects of adenosine-induced hypotension on myocardial hemodynamics and metabolism in fentanyl anesthetized patients with peripheral vascular disease. Anesthesiology 1988; 68 (3): 416-21
188. 188. Owall A, Sollevi A. Myocardial effects of adenosine-and sodium nitroprusside-induced hypotension: a comparative study in patients anaesthetized for abdominal aortic aneurysm surgery. Acta Anaesthesiol Scand 1991; 35 (3): 216-20
189. 189. Sollevi A, Lagerkranser M, Irestedt L, et al. Controlled hypotension with adenosine in cerebral aneurysm surgery. Anesthesiology 1984; 61 (4): 400-5
190. 190. Owall A, Gordon E, Lagerkranser M, et al. Clinical experience with adenosine for controlled hypotension during cerebral aneurysm surgery. Anesth Analg 1987; 66 (3): 229-34
191. 191. Owall A, Lagerkranser M, Sollevi A. Effects of adenosine-induced hypotension on myocardial hemodynamics and metabolism during cerebral aneurysm surgery. Anesth Analg 1988; 67 (3): 228-32
192. 192. Lagerkranser M, Bergstrand G, Gordon E, et al. Cerebral blood flow and metabolism during adenosine induced hypotension in patients undergoing cerebral aneurysm surgery. Acta Anaesthesiol Scand 1989; 33 (1): 15-20
193. 193. Fukunaga AF, Ikeda K, Matsuda I. ATP-induced hypotensive anesthesia during surgery. Anesthesiology 1982; 57 (3): A65
194. 194. Fukunaga AF, Sodeyama O, Matsuzaki Y, et al. Hemodynamic and metabolic changes of ATP-induced hypotension during surgery. Anesthesiology 1983; 59 (3): A12
195. 195. Colson P, Saussine M, Gaba S, et al. Vascular effects of adenosine-triphosphate. Ann Fr Anesth Reanim 1991; 10 (3): 251-4
196. 196. Segerdahl M, Persson E, Ekblom A, et al. Peroperativc adenosine infusion reduces isoflurane concentrations during general anesthesia for shoulder surgery. Acta Anaesthesiol Scand 1996; 40 (7): 792-7
197. 197. Aso Y, Tajima A, Suzuki K, et al. Intraoperative blood pressure control by ATP in pheochromocytoma. Urology 1986; 27 (6): 512-20
198. 198. Bindslev L, Sollevi A, Groendal S, et al. Adenosine: a new drug for blood pressure control during pheochromocytoma removal. Acta Anaesthesiol Scand Suppl 1987; 86 (31): 109
199. 199. Grondal S, Bindslev L, Sollevi A, et al. Adenosine: a new anti-hypertensive agent during pheochromocytoma removal. World J Surg 1988; 12 (5): 581-5
200. 200. Torssell L, Ekestrom S, Sollevi A. Adenosine-induced increase in graft flow during coronary bypass surgery. Scand J Thorac Cardiovasc Surg 1989; 23 (3): 235-9
201. 201. Rubin LJ. Vasodilators and pulmonary hypertension: where do we go from here? Am Rev Respir Dis 1987; 134: 287
202. 202. Gaba SJ, Prefaut C. Comparison of pulmonary and systemic effects of adenosine triphosphate in chronic obstructive pulmonary disease. ATP: a pulmonary controlled vasoregulator? Eur Respir J 1990; 3 (4): 450-5
203. 203. Fullerton DA, Jaggers J, Jones SD, et al. Adenosine for retractory pulmonary hypertension. Ann Thorac Surg 1996; 62 (3): 874-7
204. 204. Paidas CN, Dudgeon DL, Haller Jr JA, et al. Adenosine triphosphate: a potential therapy for hypoxic pulmonary hypertension. J Pediatr Surg 1988; 23 (12): 1154-60
205. 2 during pulmonary hypertension in lambs. J Appl Physiol 1990; 69 (5): 1836-42
206. 206. Konduri GG, Theodorou AA, Mukhopadhyay A, et al. Adenosine triphosphate and adenosine increase the pulmonary blood flow to postnatal levels in fetal lambs. Pediatr Res 1992; 31 (5): 451-7
207. 207. Paidas CN, Dudgeon DL, Malter Jr JA, et al. Adenosine triphosphate (ATP) treatment of hypoxic pulmonary hypertension (HPH): comparison of dose dependence in pulmonary and renal circulations. J Surg Res 1989; 46 (4): 374-9
208. 208. Kaapa P, Jahnukainen T, Gronlund J, et al. Adenosine triphosphate treatment for meconium aspiration-induced pulmonary hypertension in pigs. Acta Physiol Scand 1997; 160 (3): 283-9
209. 209. Reid PG, Fraser AG, Watt AH, et al. Acute haemodynamic effects of intravenous infusion of adenosine in conscious man. Eur Heart J 1990; 11 (11): 1018-28
210. 210. Gaba SJ, Bourgouin-Karaouni D, Dujols P, et al. Effects of adenosine triphosphate on pulmonary circulation in chronic obstructive pulmonary disease. ATP: a pulmonary vasoregulator? Am Rev Respir Dis 1986; 134 (6): 1140-4
211. 211. Gaba S, Didier C, Cohendy R, et al. Effects vasculaires pulmonaires et systemiques de l'ATP chez l'Homme. C R Seances Soc Biol Fil 1986; 180: 568-73
212. 2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects. Circulation 1994; 90 (3): 1287-93
213. 213. Gerasirnov NM, Guliamov DS, Karimova TZ, et al. Biologically active substances during treatment of pulmonary hypertension with ATP infusions immediately after general anesthesia and surgery of hypervolemic congenital heart defects. Anesteziol Reanimatol 1994 (3): 14-7
214. 214. Drury AN, Szent-Gyorgi A. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol (Lond) 1929; 68: 213-37
215. 215. Jezer A, Oppenheimer BS, Schwartz SP. The effect of adenosine on cardiac irregularities in man. Am Heart J 1934; 9: 252-9
216. 216. Somlo E. Adenosine triphosphate in paroxysmal tachycardia. Lancet 1955; 1: 1125
217. 217. Rankin AC, Oldroyd KG, Chong E, et al. Adenosine or adenosine triphosphate for supraventricular tachycardias? Comparative double-blind randomized study in patients with spontaneous or inducible arrhythmias. Am Heart J 1990; 119 (2): 316-23
218. 218. Sollevi A, Lagerkranser M, Andreen M, et al. Relationship between arterial and venous adenosine levels and vasodilatation during ATP and adenosine infusion in dogs. Acta Physiol Scand 1984; 120 (2): 171-6
219. 219. De Wolf D, Rondia G, Verhaaren H, et al. Adenosine triphosphate treatment for supraventricular tachycardia in infants. Eur J Pediatr 1994; 153 (11): 793-6
220. 220. Gonzalez de Dios J, Burgueros Valero M, Garcia Guereta L, et al. Adenosine triphosphate (ATP) in the management of paroxysmal supraventricular tachycardia: experience in the neonatal. Rev Esp Cardiol 1995; 48 (4): 260-5
221. 221. Clarke B, Till J, Rowland E, et al. Rapid and safe termination of supraventricular tachycardia in children by adenosine. Lancet 1987; 1 (8528): 299-301
222. 222. Paret G, Steinmetz D, Kuint J, et al. Adenosine for the treatment of paroxysmal supraventricular tachycardia in full-term and preterm newborn infants. Am J Perinatol 1996; 13 (6): 343-6
223. 223. Belhassen B, Glick A, Laniado S. Comparative clinical and electrophysiologic effects of adenosine triphosphate and verapamil on paroxysmal reciprocating junctional tachycardia. Circulation 1988; 77 (4): 795-805
224. 224. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Ann Intern Med 1990; 113 (2): 104-10
225. 225. Viskin S, Belhassen B, Sheps D, et al. Clinical and electrophysiologic effects of magnesium sulfate on paroxysmal supraventricular tachycardia and comparison with adenosine triphosphate. Am J Cardiol 1992; 70 (9): 879-85
226. 226. Roig Garcia JJ, Jimenez Murillo LM, Clemente Millan MJ, et al. The clinical usefulness and efficacy of adenosine triphosphate in an emergency service. Rev Clin Esp 1994; 194 (8): 594-8
227. 227. Sethi KK, Singh B, Kalra GS, et al. Comparative clinical and electrophysiologic effects of adenosine and verapamil on termination of paroxysmal supraventricular tachycardia. Indian Heart J 1994; 46 (3): 141-4
228. 228. Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997; 127 (6): 417-22
229. 229. Gil Madre J, Lazaro Rodriguez S, Sentenac Merchan G, et al. Adenosine triphosphate in the treatment of supraventricular paroxysmal tachycardia: a comparison with verapamil. Rev Esp Cardiol 1995; 48 (1): 55-8
230. 230. Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med 1995; 25 (5): 649-55
231. 231. Ferreira JF, Pamplona D, Cesar LA, et al. Comparative study between verapamil and adenosine triphosphate in the treatment of paroxysmal supraventricular tachycardia. Arq Bras Cardiol 1996; 66 (2): 55-7
232. 232. Brady Jr WJ, DcBehnke DJ, Wickman LL, et al. Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med 1996; 3 (6): 574-85
233. 233. Munoz A, Leenhardt A, Sassine A, et al. Therapeutic use of adenosine for terminating spontaneous paroxysmal supraventricular tachycardia. Eur Heart J 1984; 5 (9): 735-8
234. 234. Brandao L, de Sousa J, Barreiros MC, et al. Efficacy and safety of adenosine triphosphate in the control of supraventricular paroxysmal tachycardia [in Portuguese]. Rev Port Cardiol 1994; 13 (3): 197-202, 191
235. 235. Rankin AC, Oldroyd KG, Chong E, et al. Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J 1989; 62 (3): 195-203
236. 236. Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med 1990; 88 (4): 337-43
237. 237. Griffith MJ, Linker NJ, Ward DE, et al. Adenosine in the diagnosis of broad complex tachycardia. Lancet 1988; 1 (8587): 672-5
238. 238. Coyne E, Van de Streek P, Belvedere D, et al. A prospective study comparing thallium-201 imaging after intravenous adenosine infusion and exercise testing in the diagnosis of coronary artery disease. Eur J Nucl Med 1990; 16: S194
239. 239. Verani MS, Mahmarian JJ, Hixson JB, et al. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 1990; 82 (I): 80-7
240. 240. Ferreira J, Gil VM, Ventosa A, et al. Effectiveness and safety of coronary vasodilation with adenosine triphosphate with thallium-201 for the diagnosis of coronary disease. Rev Port Cardiol 1995; 14 (3): 215-24, 188
241. 241. Wang FP, Amanullah AM, Kiat H, et al. Diagnostic efficacy of stress technelium 99m-labelled sestamibi myocardial perfusion single-photon emission computed tomography in detection of coronary artery disease among patients over age 80. J Nucl Cardiol 1995; 2 (5): 380-8
242. 242. Amanullah AM, Berman DS, Hachamovitch R, et al. Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT. Am J Cardiol 1997; 80 (2): 132-7
243. 243. Vaduganathan P, He ZX, Raghavan C, et al. Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block: exercise, adenosine or dobutamine imaging? J Am Coll Cardiol 1996; 28 (3): 543-50
244. 244. Djordjcvic-Dikic AD, Ostojic MC, Beleslin BD, et al. High dose adenosine stress echocardiography for noninvasive detection of coronary artery disease. J Am Coll Cardiol 1996; 28 (7): 1689-95
245. 245. Mahmarian JJ, Boyce TM, Goldberg RK, et al. Quantitative exercise thallium-201 single photon emission computed tomography for the enhanced diagnosis of ischemic heart disease. J Am Coll Cardiol 1990; 15 (2): 318-29
246. + transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986; 78 (5): 1245-52
247. 247. Puchelle E, de Bentzmann S, Zahm JM. Physical and functional properties of airway secretions in cystic fibrosis - therapeutic approaches. Respiration 1995; 62 Suppl. 1: 2-12
248. 2+ and cAMP. Am J Physiol 1992; 263 (2): L232-42
249. 249. Kim KC, Lee BC. P2 purinoceptor regulation of mucin release by airway goblet cells in primary culture. Br J Pharmacol 1991; 103 (1): 1053-6
250. 250. Davis CW, Dowell ML, Lethem M, et al. Goblet cell degranulation in isolated canine tracheal epithelium: response to exogenous ATP, ADP, and adenosine. Am J Physiol 1992; 262 (5): C1313-23
251. 251. Lethem MI, Dowell ML, Van Scott M, et al. Nucleotide regulation of goblet cells in human airway epithelial explants: normal exocytosis in cystic fibrosis. Am J Respir Cell Mol Biol 1993; 9 (3): 315-22
252. 252. Merten MD, Breittmayer JP, Figarella C, et al. ATP and UTP increase secretion of bronchial inhibitor by human tracheal gland cells in culture. Am J Physiol 1993; 265 (5): L479-84
253. 253. Jiang C, Finkbeiner WE, Widdicombe JH, et al. Altered fluid transport across airway epithelium in cystic fibrosis. Science 1993; 262 (5132): 424-7
254. 254. Benali R, Pierrot D, Zahm JM, et al. Effect of extracellular ATP and UTP on fluid transport by human nasal epithelial cells in culture. Am J Respir Cell Mol Biol 1994; 10 (4): 363-8
255. 255. Olivier KN, Bennett WD, Hohneker KW, et al. Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate +/-amiloride in normal human adults. Am J Respir Crit Care Med 1996; 154 (1): 217-23
256. 256. Knowles MR, Clarke LL, Boucher RC. Extracellular ATP and UTP induce chloride secretion in nasal epithelia of cystic fibrosis patients and normal subjects in vivo. Chest 1992; 101 (3): 60S-3S
257. 257. Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 1983; 15 (2): 161-5
258. 258. Bennett WD, Olivier KN, Zeman KL, et al. Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996; 153 (6): 1796-801
259. 259. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322 (17): 1189-94
260. 260. Schneeberger AL, Thompson RT, Driedger AA, et al. Effect of cancer on the in vivo energy state of rat liver and skeletal muscle. Cancer Res 1989; 49 (5): 1160-4
261. 261. Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer: the response to glucose infusion and parenteral feeding. Ann Surg 1987; 205 (4): 368-76
262. 262. Drott C, Persson H, Lundholm K. Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin Physiol 1989; 9 (5): 427-39
263. 263. Lundholm K, Bylund AC, Holm J, et al. Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 1976; 12 (6): 465-73
264. 264. Nixon DW, Heymsfield SB, Cohen AE, et al. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 1980; 68 (5): 683-90
265. 265. Shapot VS, Blinov VA. Blood glucose levels and gluconeogenesis in animals bearing transplantable tumors. Cancer Res 1974; 34 (8): 1827-32
266. 266. Lundholm K, Edstrom S, Karlberg I, et al. Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer 1982; 50 (6): 1142-50
267. 267. Dagnelie PC, Bell JD, Williams SC, et al. Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors. Lipids 1994; 29 (3): 195-203
268. 268. Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993; 11 (10): 2043-9
269. 269. Chlebowski RT, Palomares MR, Lillington L, et al. Recent implications of weight loss in lung cancer management. Nutrition 1996; 12 (1): S43-7
270. 270. Dagnelie PC, Bell JD, Barnard ML, et al. Potential of nuclear magnetic resonance spectroscopy for studies of n-3 fatty acid metabolism in plasma, liver and adipose tissue. Omega 1993; 3: 27-34
271. 271. Tsuburaya A, Blumberg D, Burt M, et al. Energy depletion in the liver and in isolated hepatocytes of tumor-bearing animals. J Surg Res 1995; 59 (4): 421-7
272. 272. Haskell CM, Mendoza E, Pisters KM, et al. Phase II study of intravenous adenosine triphosphate (ATP) in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 1998; 16: 81-5
273. 273. Fang WG, Pirnia F, Bang YJ, et al. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J Clin Invest 1992; 89 (1): 191-6
274. 274. Vandewalle B, Hornez L, Revillion F, et al. Effect of extracellular ATP on breast tumor cell growth, implication of intracellular calcium. Cancer Lett 1994; 85 (1): 47-54
275. 275. Hatta Y, Aizawa S, Horikoshi A, et al. Selective killing of murine leukemic cells by adenosine triphosphate (ATP): a study of the value of autologous bone marrow transplantation. Intern Med 1993; 32 (10): 768-72
276. 276. Hatta Y, Aizawa S, Itoh T, et al. Cytotoxic effect of extracellular ATP on L1210 leukemic cells and normal hemopoietic stem cells. Leuk Res 1994; 18 (8): 637-41
277. 277. Belzer I, Friedberg I. ATP-resistant variants of transformed mouse fibroblasts. J Cell Physiol 1989; 140 (3): 524-9
278. 278. Roding TJ. De intra-arteriele toediening van ATP aan cen bij de rat geimplanteerde tumor [thesis]. 1977; (Ch. 6): 71-92
279. 279. Nayak KK, Maity P, Bhattacharyya R, et al. Antitumor activities of copper-ATP complex on transplantable murine lymphoma. Pharmacology 1990; 41 (6): 350-6
280. 280. Froio J, Abraham EH, Soni R, et al. Effect of intraperitoneal ATP on tumor growth and bone marrow radiation tolerance. Acta Oncol 1995; 34 (3): 419-22
281. 281. Pal S, Nayak KK, Maity P. Investigation on phosphate dependent glutaminase (EC 3.5.1.2) activity in host tissues of EAC-bearing mice and response of liver EC 3.5.1.2 on Cu-ATP therapy. Cancer Lett 1991; 58 (1-2): 151-3
282. 282. Maymon R, Bar-Shira Maymon B, Cohen-Armon M, et al. Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines. Biochim Biophys Acta 1994; 1201 (2): 173-8
283. 283. Fishman P, Bar-Yehuda S. Extracellular adenosine acts as a chemoprotective agent. Proc Am Assoc Cancer Res 1998; 39 (32): 3196
284. 284. Baha T, Fukui M, Takeshita I, et al. Selective enhancement of intratumoral blood flow in malignant gliomas using intraarterial adenosine triphosphate. J Neurosurg 1990; 72 (6): 907-11
285. 285. Szeinfeld D, de Villiers N. Response of normal BALB/c mouse tissue to p (66 MeV)/Be fast neutron radiation: protection by exogenous ATP. Strahlenther Onkol 1992; 168 (3): 174-8
286. 286. Szeinfeld D. The multifactorial role of ATP in repair processes and radioprotection. Med Hypotheses 1990; 32 (3): 225-9
287. 287. Szeinfeld D, Blekkenhorst C. Effect of X irradiation on adenosine triphosphate and glucose-6-phosphate dehydrogenase in the CaNT mouse tumor. Radiat Res 1987; 110 (2): 305-9
288. 288. Szeinfeld D, De Villiers N. Radioprotective properties of ATP and modification of acid phosphatase response after a lethal dose of whole body p (66MeV)/Be neutron radiation to BALB/c mice. Cancer Biochem Biophys 1992; 13 (2): 123-32
289. 289. Szeinfeld D, de Villiers N. Cholinesterase response in the rhabdomyosarcoma tumor and small intestine of the BALB/c mice and the radioprotectivc actions of exogenous ATP after lethal dose of neutron radiation. Strahlenther Onkol 1993; 169 (5): 311-6
290. 290. Lee JW, Filkins JP. Exogenous ATP and carbohydrate metabolism in the rat liver. Circ Shock 1987; 22 (3): 205-19
291. 291. Nikolov I, Rogozkin VD, Pantev T, et al. Protection of monkeys against prolonged gamma-irradiation. Strahlenther Onkol 1986; 162 (3): 200-4
292. 292. Tikhomirova MV, Iashkin PN, Fedorenko BS, et al. Radiation-protective effectiveness of ATP and adenosine against high-energy protons. Kosm Biol Aviakosm Med 1984; 18 (5): 75-7
293. 293. Senagore AJ, Milsom JW, Walshaw RK, et al. Adenosine triphosphate-magnesium chloride in radiation injury. Surgery 1992; 112 (5): 933-9
294. 294. Vorozhtsova SV, Fedorenko BS, Andrushchenko VN, et al. Biological effect of 9 GeV protons and the radioprotective effect of ATP and AMP on epithelial cells of the mouse cornea. Radiobiologiia 1987; 27 (6): 779-83
295. 295. Perrot B, Clozel JP, Faivre G. Effect of adenosine triphosphate on the accessory pathways. Eur Heart J 1984; 5 (5): 382-93
296. 296. Watt AH, Bernard MS, Webster J, et al. Intravenous adenosine in the treatment of supraventricular tachycardia: a dose-ranging study and interaction with dipyridamole. Br J Clin Pharmacol 1986; 21 (2): 227-30
297. 297. Biaggioni I, Olafsson B, Robertson RM, et al. Cardiovascular and respiratory effects of adenosine in conscious man: evidence for chemoreceptor activation. Circ Res 1987; 61 (6): 779-86
298. 298. Jonzon B, Sylven C, Beermann B, et al. Adenosine receptor mediated stimulation of ventilation in man. Eur J Clin Invest 1989; 19 (1): 65-71
299. 299. Conradson TB, Dixon CM, Clarke B, et al. Cardiovascular effects of infused adenosine in man: potentiation by dipyridamole. Acta Physiol Scand 1987; 129 (3): 387-91
300. 300. Sylven C, Beermann B, Jonzon B, et al. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J 1986; 293 (6541): 227-30
301. 301. Domanovits H, Laske H, Stark G, et al. Adenosine for the management of patients with tachycardias - a new protocol. Eur Heart J 1994; 15 (5): 589-93
302. 302. Belhassen B, Pelleg A, Shoshani D, et al. Atrial fibrillation induced by adenosine triphosphate. Am J Cardiol 1984; 53 (9): 1405-6
303. 303. Watt AH, Reid PG, Stephens MR, et al. Adenosine-induced respiratory stimulation in man depends on site of infusion: evidence for an action on the carotid body? Br J Clin Pharmacol 1987; 23 (4): 486-90
304. 304. Sylven C. Angina pectoris-like pain provoked by intravenous infusion of adenosine. Br Med J 1986; 293 (6556): 1240
305. 305. Sylven C, Jonzon B, Fredholm BB, et al. Adenosine injection into the brachial artery produces ischaemia like pain or discomfort in the forearm. Cardiovasc Res 1988; 22 (9): 674-8
306. 306. Sylven C, Beermann B, Edlund A, et al. Provocation of chest pain in patients with coronary insufficiency using the vasodilator adenosine. Eur Heart J 1988; 9 Suppl. N: 6-10
307. 307. Sylven C. Mechanisms of pain in angina pectoris a critical review of the adenosine hypothesis. Cardiovasc Drugs Ther 1993; 7 (5): 745-59
308. 308. Crea F, Pupita G, Galassi AR, et al. Role of adenosine in pathogenesis of anginal pain. Circulation 1990; 81 (1): 164-72
309. 309. Lagerqvist B, Sylven C, Theodorsen E, et al. Adenosine induced chest pain: a comparison between intracoronary bolus injection and steady state infusion. Cardiovasc Res 1992; 26 (8): 810-4
310. 310. Straat E, Henriksson P, Edlund A. Adenosine provokes myocardial ischaemia in patients with ischaemic heart disease without increasing cardiac work. J Intern Med 1991; 230 (4): 319-23
311. 311. O'Keefe Jr JH, Bateman TM, Silvestri R, et al. Safety and diagnostic accuracy of adenosine thallium-201 scintigraphy in patients unable to exercise and those with left bundle branch block. Am Heart J 1992; 124 (3): 614-21